KRAS and neoplasm: In lung metastases, IDS showed no association with mutations in EGFR (n = 95, p = 0.703), KRAS (n = 77, p = 0.476), and BRAF (n = 71, p = 0.581), or PD‐L1 Tumour Proportion Score (TPS: >1% and >50%; n = 49, p = 0.880).